The goal of Cancer Prevention Pharmaceuticals, Inc. (CPP) is to develop "prevention therapies" for people with elevated risk for cancer.
CPP's approach is: "Don't wait until you get cancer. Treat the risk factors."
This approach of treating risk factors has not only saved lives in heart disease, neurovascular disease, and infectious diseases;
it has resulted in multi-billion dollar blockbuster markets for "prevention therapeutics" such as cholesterol-lowering drugs, blood pressure-lowering drugs, and vaccines.
Cancer Prevention Pharmaceuticals, Inc. is developing novel therapeutic agents, diagnostics, and lifestyle recommendations that make possible the treatment of risk factors for cancer. We were founded by some of the most highly respected leaders in preclinical and clinical cancer prevention research. The CPP team has well over 100 years of combined drug development and research experience. CPP is working closely with the National Cancer Institute (NCI), the Food and Drug Administration (FDA), and the European Medicines Agency (EMA) to make prevention therapies a reality for those at-risk for cancer.
Recently, in a placebo-controlled clinical trial, CPP demonstrated remarkable efficacy of a specific combination chemoprevention regimen for the prevention of recurrence of colon polyps—the forerunners of colon cancer.
The time is right to apply "Risk Reduction" paradigms to cancer. Learn more . . .
UA Spin-off to Test Cancer Prevention . . .
CPP Receives Positive . . .
Success in Clinical Trials . . .
Biotech Firms Get Funding . . .
Tucson Cancer Prevention Firm is BioIndustry Winner . . .
Company Gets U.S. Grant for Research of Cancer Drug . . .
CPP Wins Fast Start Award and Federal Grant . . .